Medicine
Susan M. Chang, P. Wen, T. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, K. Fink, H. Robins, L. Angelis, J. Raizer, K. Hess, K. Aldape, K. Lamborn, J. Kuhn, J. Dancey, M. Prados, North American Brain Tumor Consortium and the National C Institute
2005.8.1INVESTIGATIONAL NEW DRUGS
tlooto Summary
CCI-779 was well tolerated at this dose schedule; however, there was no evidence of efficacy in patients with recurrent GBM, and the low toxicity profile may merit exploration in combination with other modalities.
Abstract
Abstract is not available.
Citation format
CHANG, Susan M., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. INVESTIGATIONAL NEW DRUGS, 2005, 23: 357–361.